1201 related articles for article (PubMed ID: 20484021)
1. CXCL12 (SDF-1)/CXCR4 pathway in cancer.
Teicher BA; Fricker SP
Clin Cancer Res; 2010 Jun; 16(11):2927-31. PubMed ID: 20484021
[TBL] [Abstract][Full Text] [Related]
2. Chemokine receptor CXCR4: role in gastrointestinal cancer.
Lombardi L; Tavano F; Morelli F; Latiano TP; Di Sebastiano P; Maiello E
Crit Rev Oncol Hematol; 2013 Dec; 88(3):696-705. PubMed ID: 24120239
[TBL] [Abstract][Full Text] [Related]
3. [Clinical relevance of chemokine receptor CXCR4].
Gębura K; Bogunia-Kubik K
Postepy Hig Med Dosw (Online); 2012 May; 66():252-66. PubMed ID: 22706111
[TBL] [Abstract][Full Text] [Related]
4. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
[TBL] [Abstract][Full Text] [Related]
5. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion.
Kucia M; Jankowski K; Reca R; Wysoczynski M; Bandura L; Allendorf DJ; Zhang J; Ratajczak J; Ratajczak MZ
J Mol Histol; 2004 Mar; 35(3):233-45. PubMed ID: 15339043
[TBL] [Abstract][Full Text] [Related]
6. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
7. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
8. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis.
Kucia M; Reca R; Miekus K; Wanzeck J; Wojakowski W; Janowska-Wieczorek A; Ratajczak J; Ratajczak MZ
Stem Cells; 2005 Aug; 23(7):879-94. PubMed ID: 15888687
[TBL] [Abstract][Full Text] [Related]
9. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
10. CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target.
Terasaki M; Sugita Y; Arakawa F; Okada Y; Ohshima K; Shigemori M
Brain Tumor Pathol; 2011 Apr; 28(2):89-97. PubMed ID: 21210239
[TBL] [Abstract][Full Text] [Related]
11. CXC chemokine receptor 4 (CXCR4) blockade in cancer treatment.
Bao S; Darvishi M; H Amin A; Al-Haideri MT; Patra I; Kashikova K; Ahmad I; Alsaikhan F; Al-Qaim ZH; Al-Gazally ME; Kiasari BA; Tavakoli-Far B; Sidikov AA; Mustafa YF; Akhavan-Sigari R
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7945-7968. PubMed ID: 36905421
[TBL] [Abstract][Full Text] [Related]
12. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
[TBL] [Abstract][Full Text] [Related]
13. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
14. The good and bad faces of the CXCR4 chemokine receptor.
Teixidó J; Martínez-Moreno M; Díaz-Martínez M; Sevilla-Movilla S
Int J Biochem Cell Biol; 2018 Feb; 95():121-131. PubMed ID: 29288743
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell.
Wang Z; Sun J; Feng Y; Tian X; Wang B; Zhou Y
Tumour Biol; 2016 Jul; 37(7):8515-28. PubMed ID: 27079871
[TBL] [Abstract][Full Text] [Related]
16. The role of stromal-derived factor-1--CXCR7 axis in development and cancer.
Maksym RB; Tarnowski M; Grymula K; Tarnowska J; Wysoczynski M; Liu R; Czerny B; Ratajczak J; Kucia M; Ratajczak MZ
Eur J Pharmacol; 2009 Dec; 625(1-3):31-40. PubMed ID: 19835865
[TBL] [Abstract][Full Text] [Related]
17. CXCL12/CXCR4 signal transduction in diseases and its molecular approaches in targeted-therapy.
Mousavi A
Immunol Lett; 2020 Jan; 217():91-115. PubMed ID: 31747563
[TBL] [Abstract][Full Text] [Related]
18. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
[TBL] [Abstract][Full Text] [Related]
19. CXCL14 antagonizes the CXCL12-CXCR4 signaling axis.
Hara T; Tanegashima K
Biomol Concepts; 2014 May; 5(2):167-73. PubMed ID: 25372750
[TBL] [Abstract][Full Text] [Related]
20. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
